Revenue segments as reported by the company.

Products

Premiums

Services

Net investment income

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Benefit costs

Operating expenses

Goodwill impairment

Store impairments

Opioid litigation charges

Loss on assets held for sale

Restructuring charge

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CVS Health

Aetna is an American managed health care company, which sells traditional and consumer directed health care insurance plans and related services, such as medical, pharmaceutical, dental, behavioral health, long-term care, and disability plans. Aetna is a member of the Fortune 500.

Aetna

CVS Pharmacy is a subsidiary of the American retail and health care company CVS Health, headquartered in Woonsocket, Rhode Island. It was also known as, and originally named the Consumer Value Store and was founded in Lowell, Massachusetts, in 1963. The chain was owned by its original holding company Melville Corporation since its inception until its current parent company CVS Health was spun off into its own company in 1996. CVS Pharmacy is currently the largest pharmacy chain in the United States by number of locations (over 9,600 as of 2016) and total prescription revenue. As the retail pharmacy division of CVS Health, it ranks as the 7th largest U.S. corporation according to Fortune 500 in 2016. CVS Pharmacy's leading competitor Walgreens Boots Alliance ranked 37th.

CVS Pharmacy

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

CVS Health exceeds Q4 expectations, eyes growth with Oak Street

CVS Health's strong financial performance in 2022, driven by revenue growth and exceeding EPS expectations, positions the company well for future growth.
The acquisition of Oak Street Health presents opportunities to expand into primary care and improve long-term earnings growth, despite challenges in maintaining retail performance.

CVS Health excels in Q1, eyes growth through acquisitions and innovation

CVS Health's strong financial performance, strategic acquisitions, and customer-centric initiatives position the company for sustained growth and competitive advantage.
While facing challenges in the evolving healthcare landscape, CVS Health's focus on innovation, affordability, and operational efficiency provides a solid foundation for future success.
By capitalizing on opportunities in growth, synergies, and healthcare services, CVS Health can navigate industry headwinds and drive long-term value creation for stakeholders.

CVS Health reports robust Q2 earnings, eyes growth opportunities

CVS Health's Q2 2023 performance reflects strong financial results and strategic acquisitions driving growth.
Despite challenges like higher costs and restructuring charges, the company remains confident in its ability to deliver outstanding performance.
Opportunities lie in expanding Medicaid contracts, biosimilar market establishment, and clinic openings for at-risk populations.
Overall, CVS Health's focus on cost optimization, digital sales growth, and patient engagement positions it well for future success.

CVS Health reports robust Q3 earnings and strategic growth plans

CVS Health's Q3 performance reflects strong financial results and strategic initiatives across its segments, positioning the company for sustainable growth.
While facing challenges like declining vaccine demand and contract losses, CVS Health is focused on leveraging opportunities in biosimilars and cost-saving solutions.
The company's commitment to operational excellence, innovation, and workforce investment underscores its strategic vision for becoming a leading health solutions provider.
With a clear focus on growth drivers and mitigating challenges, CVS Health is poised to capitalize on market opportunities and deliver value to shareholders.

CVS Health reports robust Q4 earnings, eyes Medicare margin recovery

CVS Health's Q4 2023 earnings call highlighted strong financial performance, a cautious stance on Medicare Advantage utilization, and a focus on transforming healthcare delivery. The company is committed to margin recovery, growth, and enhancing customer experience while addressing challenges in Medicare Advantage trends and cost pressures.

CVS Health faces Medicare Advantage challenges, focuses on margin improvement

CVS Health's Q1 2024 earnings call highlighted strong financial performance, challenges in the Medicare Advantage business, and a focus on improving margins. The company showcased strengths in the biosimilar market and Pharmacy & Consumer Wellness segment while addressing issues impacting Health Care Benefits and Services segments.

CVS Health's Q2 2024 performance reflects strong financial results, cost savings, and innovative initiatives in pharmacy services.
The company faces challenges in the Health Care Benefits segment but is actively addressing them through leadership changes and operational improvements.
Opportunities for growth include driving margin improvements, expanding digital reach, and educating stakeholders on the value delivery of PBMs.
Expectation of margin recovery in Medicare Advantage and double-digit EPS growth in 2025 highlight CVS Health's strategic focus on operational efficiencies and cost savings.

CVS Health reports robust Q3 earnings, focuses on growth strategies

CVS Health's Q3 2024 performance was marked by strong financial results, leadership changes, and segment-specific challenges and successes. The company is focused on leveraging opportunities in strategic initiatives and addressing areas for improvement to drive future growth.

Revenue

Cost of revenue

Gross profit

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

WOONSOCKET, R.I. , Sept. 25, 2024 /PRNewswire/ -- CVS Health® (NYSE: CVS) is actively preparing for Hurricane Helene's landfall in Florida tomorrow.

CVS Health supporting customers, patients, members and colleagues as Hurricane Helene approaches

More than 7,000 workers to hold strike vote this week amid accusations of staff shortages and expensive healthcare

‘Can't afford health insurance': California CVS workers take strike vote

Cigna

UnitedHealth Group

The FTC is suing CVS Health, Cigna, and UnitedHealth Group because of alleged uncompetitive PBM practices. Their PBM units are major revenue sources for all three healthcare companies.

Are CVS Health, Cigna, and UnitedHealth Group Stocks Bad News Buys With the FTC's PBM Crackdown?

With the Federal Trade Commission (FTC) taking a scalpel to the pharmacy benefit managers (PBMs) of UnitedHealth Group Inc UNH, CVS Health Corp CVS and Cigna Group CI, investors are left wondering which health giant can best weather the storm.

UnitedHealth Vs. CVS Vs. Cigna: Which Health Stock Will Beat The FTC's Regulatory Heat?

The FTC sued UnitedHealth Group's Optum unit, CVS Caremark and Cigna's Express Scripts for allegedly steering diabetes patients towards higher priced insulin.

UnitedHealth, CVS Caremark, Express Scripts sued by FTC over skyrocketing insulin prices

Pharmacy-benefit managers owned by CVS, Cigna and UnitedHealth “artificially inflated” prices for lifesaving medications, regulator alleges.

FTC sues prescription-drug middlemen over insulin prices, says drugmakers are also ‘on notice'

Humana

The U.S. Federal Trade Commission said on Friday it was suing the country's three largest pharmacy benefit managers, accusing them of abusing their power and rigging the pharmaceutical supply chain to artificially inflate the cost of insulin.

Explainer: Why are US pharmacy benefit managers under fire?

The Federal Trade Commission on Friday sued three large U.S. health companies that negotiate insulin prices, arguing the drug middlemen boost their profits while "artificially" inflating costs for patients.  The suit targets the three biggest so-called pharmacy benefit managers, UnitedHealth Group's Optum Rx, CVS Health's Caremark and Cigna's Express Scripts, and their affiliated group purchasing organizations.

FTC sues drug middlemen for allegedly inflating insulin prices

Gilead Sciences

Pfizer

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields

WOONSOCKET, R.I. , Sept. 19, 2024 /PRNewswire/ -- CVS Health (NYSE: CVS) has announced that its board of directors has approved a quarterly dividend of sixty-six and one-half cents ($0.665 cents) per share on the Common Stock of the Corporation.

CVS Health announces quarterly dividend

Baxter

Bristol-Myers

Healthcare is undervalued despite being the top sector for earnings growth, making it an attractive investment with solid fundamentals and the potential for explosive returns in 2025. Investing in healthcare ETFs or individual undervalued healthcare stocks can capitalize on the sector's recovery and expected double-digit growth through 2026. Screening for blue-chip healthcare stocks with solid fundamentals and fair valuations can yield superior returns, including these five coiled spring blue chips.

5 Incredible Healthcare High-Yield Blue-Chip Bargain Buys For 2025

Citigroup

Verizon

Verizon sports a fat dividend yield of 6.6% and plenty enough cash flow to cover it. Financial services powerhouse Citigroup offers a more modest but still solid 3.6% yield.

4 Dividend Stocks to Double Up On Right Now

LOS ANGELES, CA / ACCESSWIRE / September 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against CVS Health Corporation ("CVS" or "the Company") (NYSE:CVS) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 3, 2023 and April 30, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 10, 2024.

CVS Health Corporation Is Being Sued For Securities Law Violations And The Schall Law Firm Invites Investor Participation

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Is CVS Health (CVS) a Buy as Wall Street Analysts Look Optimistic?

Despite deteriorating fundamentals and bad press, I bought a half-sized position in CVS due to its historical and relative cheapness, attractive yield, and potential for recovery. CVS trades below 9x forward PE, indicating it's priced for further deterioration, but it's historically and relatively cheap compared to peers like CI and UNH. CVS offers a 4.6% yield, making it an attractive income security, especially compared to treasury rates and other high-yield securities.

CVS's Guide May Have Reached 'Kitchen Sink' Point

LOS ANGELES, CA / ACCESSWIRE / September 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against CVS Health Corporation ("CVS" or "the Company") (NYSE:CVS) for violations of 10(b) and 20(a) of the Securities Excange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 3, 2023 and April 30, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 10, 2024.

A Securities Fraud Lawsuit Has Been Filed Against CVS Health Corporation And Shareholders With Losses Should Contact The Schall Law Firm

LOS ANGELES, CA / ACCESSWIRE / September 14, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against CVS Health Corporation ("CVS" or "the Company") (NYSE:CVS) for violations of 10(b) and 20(a) of the Securities Excange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 3, 2023 and April 30, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 10, 2024.

CVS Health Corporation May Have Violated Securities Laws And The Schall Law Firm Wants Impacted Investors To Reach Out About A Case

The latest trading day saw CVS Health (CVS) settling at $57.98, representing a +0.78% change from its previous close.

CVS Health (CVS) Rises Higher Than Market: Key Facts

LOS ANGELES, CA / ACCESSWIRE / September 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against CVS Health Corporation ("CVS" or "the Company") (NYSE:CVS) for violations of 10(b) and 20(a) of the Securities Excange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 3, 2023 and April 30, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 10, 2024.

Stockholders Can Assist The Schall Law Firm In A Securities Fraud Lawsuit Against CVS Health Corporation

Albertsons Companies

Dollar General

Certain stocks stand out as attractively priced and well-positioned for potential appreciation for value investors focused on long-term growth with a defensive approach. While not isolated from risks and challenges, the three companies discussed below trade at favorable valuations based on P/E ratios and earnings growth and offer the added benefit of dividend income, making them appealing to those seeking steady returns and compounding growth.

3 Overlooked Stocks With Strong Value and Dividend Potential

CVS Health announces that nearly 400 CVS Pharmacy locations in Massachusetts have started offering hormonal contraceptive prescribing services.

CVS Stock Gains From Its Birth Control Prescribing Service Launch

LOS ANGELES, CA / ACCESSWIRE / September 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against CVS Health Corporation ("CVS" or "the Company") (NYSE:CVS) for violations of 10(b) and 20(a) of the Securities Excange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 3, 2023 and April 30, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 10, 2024.

CVS Health Corporation May Have Violated Securities Laws And The Schall Law Firm Invites Investors To Partake In A Case

CVS pharmacists can now evaluate patients and prescribe hormonal contraceptives WOONSOCKET, R.I. , Sept. 12, 2024 /PRNewswire/ -- CVS Health® (NYSE: CVS) today announced that CVS Pharmacy® locations in Massachusetts are now offering hormonal contraceptive prescribing services.

CVS Pharmacy® launches birth control prescribing in Massachusetts

LOS ANGELES, CA / ACCESSWIRE / September 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against CVS Health Corporation ("CVS" or "the Company") (NYSE:CVS) for violations of 10(b) and 20(a) of the Securities Excange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 3, 2023 and April 30, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 10, 2024.

Shareholders Are Encouraged To Reach Out To The Schall Law Firm About A Lawsuit Against CVS Health Corporation For Securities Fraud

WOONSOCKET, R.I. , Sept. 10, 2024 /PRNewswire/ -- CVS Health® (NYSE: CVS) is actively preparing for Tropical Storm Francine, which is expected to make landfall in Louisiana as a hurricane tomorrow.

News for CVS Health Stock (CVS)